anacor pharmaceuticals inc
(ANAC:NASDAQ GM)
anacor pharmaceuticals inc (ANAC) Snapshot
|
Open
$5.03
|
Previous Close
$4.99
|
|
|
Day High
$5.28
|
Day Low
$4.92
|
|
|
52 Week High
04/19/13 - $8.25
|
52 Week Low
02/27/13 - $3.00
|
|
|
Market Cap
210.6M
|
Average Volume 10 Days
338.3K
|
|
|
EPS TTM
$-1.71
|
Shares Outstanding
40.5M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
anacor pharmaceuticals inc (ANAC) Related Businessweek News
No Related Businessweek News Foundanacor pharmaceuticals inc (ANAC) Details
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Medicis Pharmaceutical Corporation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.
anacor pharmaceuticals inc (ANAC) Top Compensated Officers
anacor pharmaceuticals inc (ANAC) Key Developments
Anacor Pharmaceuticals announced that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. for up to $45.0 million in new capital to be distributed in three tranches. Anacor borrowed the first tranche of $30.0 million upon the execution of the loan agreement on June 7, 2013 and used approximately $22.6 million to repay the remaining obligations under its loan agreement with Oxford Finance LLC and Horizon Technology Finance Corporation. Anacor expects to use the remainder of the funding for filing its New Drug Application (NDA) for tavaborole, conducting additional clinical studies of AN2728 and for general working capital. The second tranche of $10.0 million is available at Anacor's discretion through December 5, 2013, and the third tranche of $5.0 million is available upon confirmation of the U.S. Food and Drug Administration's (FDA) approval of the tavaborole NDA through the earlier of December 15, 2014 or 30 days after the FDA approval of tavaborole.
Anacor Pharmaceuticals announced that it has successfully completed its pre-NDA (New Drug Application) communications with the Food and Drug Administration (FDA) related to tavaborole, its drug candidate for the topical treatment of onychomycosis. In its pre-NDA communications, Anacor achieved concurrence from the FDA on the content and format of the proposed NDA for tavaborole including required data related to safety, efficacy, manufacturing and packaging. Anacor remains on schedule to file the NDA in mid-2013.
Anacor Pharmaceuticals, Inc. will be added to NASDAQ Biotechnology Index.
| Recently Viewed | |||
| ANAC:US | $5.20 USD | +0.21 |  |
| Company | Last | Change | |
| No competitor information is available for ANAC. | |||
| View Industry Companies | |||
Industry Analysis
ANAC
Industry Average
| Valuation | ANAC | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 17.8x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 14.6x |
|
Post a JobJobs
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
- Orlando, FL | Consult SoftPosted: May 22
Sponsored Financial Commentaries
Sponsored Links
To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
